Qiagen CEO Details Companion Dx Strategy and Near-Term Launches at UBS Life Sciences Meeting | GenomeWeb

Originally published Sept. 21.

By Turna Ray

With more than 20 collaborations with drug companies now under its belt, Qiagen is steadily penetrating the companion diagnostics market.

Since acquiring the personalized medicine company DxS in September 2009, Qiagen has netted as many as five new collaborations with drug companies "to develop companion diagnostics for their blockbuster drugs," Qiagen CEO Peer Schatz said at an investor conference this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.